<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01031186</url>
  </required_header>
  <id_info>
    <org_study_id>113324</org_study_id>
    <nct_id>NCT01031186</nct_id>
  </id_info>
  <brief_title>First Time in Human Study</brief_title>
  <acronym>FTIM</acronym>
  <official_title>A First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK356278 (PDE4 Inhibitor) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and pharmacokinetics of GSK356278 in male
      volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety, tolerability and pharmacokinetics of single ascending doses of
      GSK356278 and may assess the effect of food on GSK356278 pharmacokinetics. They study will
      assess the compound's effect on nausea, emesis and alertness. Close monitoring of
      cardiovascular parameters will be included.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 23, 2009</start_date>
  <completion_date type="Actual">April 7, 2010</completion_date>
  <primary_completion_date type="Actual">April 7, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess safety and tolerability of single escalating oral doses of GSK356278 in healthy male volunteers</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the pharmacokinetics of single escalating doses of GSK356278 in healthy male volunteers</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Depressive Disorder and Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>Cohort 1, Session 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 1, the subjects will be administered 0.5 mg GSK356278 and placebo in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Session 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 2, the subjects will be administered GSK356278 (0.5 mg and 1.5 mg) and placebo in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Session 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 3, the subjects will be administered GSK356278 (1.5 mg and 4 mg) and placebo in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Session 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 4, the subjects will be administered GSK356278 (4 mg and 8 mg) and placebo in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Session 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 5, the subjects will be administered GSK356278 8 mg and placebo in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Session 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 1, the subjects will be administered 8 mg GSK356278 and placebo in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Session 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 2, the subjects will be administered GSK356278 (8 mg and 16 mg) and placebo in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Session 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 3, the subjects will be administered GSK356278 (16 mg and 30 mg) and placebo in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Session 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 4, the subjects will be administered GSK356278 (30 mg and 50 mg) and placebo in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Session 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Dosing Session 5, the subjects will be administered GSK356278 50 mg and placebo in a fasted state. The subjects will undergo food assessment session in Session 5 incase they experience nausea. In food assessment session, the subjects will receive a dose of GSK356278 after a standard breakfast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK356278</intervention_name>
    <description>GSK356278</description>
    <arm_group_label>Cohort 2, Session 1</arm_group_label>
    <arm_group_label>Cohort 1, Session 2</arm_group_label>
    <arm_group_label>Cohort 2, Session 4</arm_group_label>
    <arm_group_label>Cohort 2, Session 5</arm_group_label>
    <arm_group_label>Cohort 1, Session 4</arm_group_label>
    <arm_group_label>Cohort 2, Session 3</arm_group_label>
    <arm_group_label>Cohort 1, Session 1</arm_group_label>
    <arm_group_label>Cohort 1, Session 5</arm_group_label>
    <arm_group_label>Cohort 1, Session 3</arm_group_label>
    <arm_group_label>Cohort 2, Session 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>PLACEBO</description>
    <arm_group_label>Cohort 2, Session 1</arm_group_label>
    <arm_group_label>Cohort 1, Session 2</arm_group_label>
    <arm_group_label>Cohort 2, Session 4</arm_group_label>
    <arm_group_label>Cohort 2, Session 5</arm_group_label>
    <arm_group_label>Cohort 1, Session 4</arm_group_label>
    <arm_group_label>Cohort 2, Session 3</arm_group_label>
    <arm_group_label>Cohort 1, Session 1</arm_group_label>
    <arm_group_label>Cohort 1, Session 5</arm_group_label>
    <arm_group_label>Cohort 1, Session 3</arm_group_label>
    <arm_group_label>Cohort 2, Session 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AST, ALT, alkaline phosphate and bilirubin less than or equal to 1.5 times upper limit
             of normal.

          -  Healthy as determined by a responsible and experienced physician based on a medical
             evaluation including medical history, physical examination, laboratory tests and
             cardiac monitoring.

          -  Males aged between 18 and 65 years inclusive at the time of signing the informed
             consent.

          -  Males must agree to appropriate forms of contraception from administration of first
             dose through to 3 months after taking the final dose.

          -  Body weight greater than or equal to 50 kg and BMI within the range of 18-29.9 m2
             (inclusive)

          -  Capable of giving written informed consent.

          -  QTcB or QTcF less than 450 msec

        Exclusion Criteria:

          -  A positive pre-study Hep B or positive Hep C result within 3 months of screening.

          -  Current or chronic history of liver disease or known hepatic or biliary abnormalities

          -  A positive pre-study alcohol and drug screen

          -  A positive test for HIV antibody.

          -  History of regular alcohol consumption within 6 months of the study defined as an
             average weekly intake of greater than 21 units or average daily intake of greater than
             3 units

          -  The subject has participated in a clinical trial and has received investigational
             product within the time period of 30 days prior to first dosing day (or 5 half-lives
             or twice the duration of the biological effect of the drug, whichever is longer)

          -  Exposure to more than 4 new chemical entities in the last 12 months prior to the first
             dosing day

          -  Use of prescription or non-prescription drugs including vitamins, herbal and dietary
             supplements within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5
             half-lives (whichever is longer) prior to the first dose unless in the opinion of the
             investigator and medical monitor the medication will not interfere with the study
             procedures or compromise subject safety.

          -  History of sensitivity to any of the study medication or history of drug or other
             allergy that in the opinion of the investigator or medical monitor contraindicates
             their participation.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 ml within a 56 day period.

          -  Unwillingness or inability to follow the procedures in the protocol.

          -  Subject is mentally or legally incapacitated.

          -  Subjects who have asthma or a history of asthma.

          -  Urinary cotinine levels indicative of smoking or history of regular use of tobacco or
             nicotine containing products within 6 months prior to screening.

          -  Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or
             pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior
             to the first dose.

          -  History of any significant psychiatric illness.

          -  Any history of suicidal behaviour or any suicidal ideation of type 4 or 5 on the
             Columbia Suicide Severity Rating Scale in the last 6 months.

          -  History of presence of clinically significant cardiac arrhythmias or other clinically
             significant cardiac disease.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/113324?search=study&amp;search_terms=113324#rs</url>
    <description>Results for study 113324 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2009</study_first_submitted>
  <study_first_submitted_qc>December 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2009</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy male volunteers</keyword>
  <keyword>GSK356278</keyword>
  <keyword>first time in man</keyword>
  <keyword>major depressive disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113324</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113324</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113324</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113324</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113324</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113324</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113324</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

